Trials / Completed
CompletedNCT03748901
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients
A Retrospective Multicenter Analysis of PD-L1 Expression in Japanese Renal Cell Carcinoma Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 830 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter retrospective study designed to compare overall survival (OS) by PD-L1 expression status in patients with RCC who have received systemic chemotherapy for recurrent or metastatic RCC, to determine whether the prognosis is worse in PD-L1-positive than in PD-L1-negative RCC. Total 600 RCC surgical specimens will be collected from patients who started systemic chemotherapy for recurrent or metastatic RCC between January 1, 2010 and December 31, 2015 at about 30 participating study sites in Japan. PD-L1 expression status (IC; immune cell) on tumor-infiltrating immune cells will be evaluated by IHC, and classified by score: IC0 (PD-L1-negative) and IC1, IC2, IC3 (PD-L1-positive). Unless otherwise specified, between-group comparisons will be performed between IC0 and IC1/2/3.
Conditions
Timeline
- Start date
- 2018-12-16
- Primary completion
- 2021-07-21
- Completion
- 2021-07-21
- First posted
- 2018-11-21
- Last updated
- 2021-08-30
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03748901. Inclusion in this directory is not an endorsement.